While the frequency of pre-existing SOX10+ melanoma cells prior to treatment was not associated with PFS, a greater increase in SOX10+ melanoma cells from baseline to progression was associated with shorter PFS under BRAF/MEK inhibition treatment (Spearman r = −0.842, p = 0.004) (Fig. 2b). This evidence concerns the gene BRAF and melanoma.